334 related articles for article (PubMed ID: 23533011)
1. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis.
Scigliano G; Ronchetti G
CNS Drugs; 2013 Apr; 27(4):249-57. PubMed ID: 23533011
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. [Brazilian Consensus on second-generation antipsychotics and metabolic disorders].
Elkis H; Gama C; Suplicy H; Tambascia M; Bressan R; Lyra R; Cavalcante S; Minicucci W
Braz J Psychiatry; 2008 Mar; 30(1):77-85. PubMed ID: 18373022
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risks of atypical antipsychotic drug treatment.
Drici MD; Priori S
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
[TBL] [Abstract][Full Text] [Related]
5. [Schizophrenia, diabetes mellitus and antipsychotics].
Gury C
Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
[TBL] [Abstract][Full Text] [Related]
6. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system.
Leung JY; Barr AM; Procyshyn RM; Honer WG; Pang CC
Pharmacol Ther; 2012 Aug; 135(2):113-22. PubMed ID: 22565090
[TBL] [Abstract][Full Text] [Related]
8. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
Monteleone P; Martiadis V; Maj M
Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
[TBL] [Abstract][Full Text] [Related]
9. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
Nikam SS; Awasthi AK
Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
[TBL] [Abstract][Full Text] [Related]
10. Differential metabolic effects of antipsychotic treatments.
Haupt DW
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S149-55. PubMed ID: 16872808
[TBL] [Abstract][Full Text] [Related]
11. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
[TBL] [Abstract][Full Text] [Related]
12. Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1).
Peluso MJ; Lewis SW; Barnes TR; Jones PB
Schizophr Res; 2013 Mar; 144(1-3):80-6. PubMed ID: 23313462
[TBL] [Abstract][Full Text] [Related]
13. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
Citrome L; Holt RI; Walker DJ; Hoffmann VP
Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
[TBL] [Abstract][Full Text] [Related]
14. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
Rzewuska M
Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
[TBL] [Abstract][Full Text] [Related]
15. Clozapine use in geriatric patients- Challenges.
Mukku SSR; Sivakumar PT; Varghese M
Asian J Psychiatr; 2018 Mar; 33():63-67. PubMed ID: 29529421
[TBL] [Abstract][Full Text] [Related]
16. [Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview].
Scheepers-Hoeks AM; Wessels-Basten SJ; Scherders MJ; Bravenboer B; Loonen AJ; Kleppe RT; Grouls RJ
Tijdschr Psychiatr; 2008; 50(10):645-54. PubMed ID: 18951343
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Effects of Antipsychotic Drugs.
Sánchez JPB; Ellenbroek BA
Curr Top Behav Neurosci; 2017; 34():1-16. PubMed ID: 27356523
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic-Induced Alterations in Lipid Turnover.
Pereira S; Au E; Agarwal SM; Wright DC; Hahn MK
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718081
[TBL] [Abstract][Full Text] [Related]
19. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.
Inoue A; Nakata Y
Jpn J Pharmacol; 2001 Aug; 86(4):376-80. PubMed ID: 11569610
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular aspects of antipsychotics.
Raedler TJ
Curr Opin Psychiatry; 2010 Nov; 23(6):574-81. PubMed ID: 20838345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
